AstraZeneca Internal Seroquel Documents Cite Cherry-Picking, Burying Data
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca agreed to unseal internal communications in Seroquel product liability litigation discussing risks associated with the drug.
You may also be interested in...
Seroquel Marketing Plan Included “Spinning The Data, aka Lilly”
Plantiffs attorneys allege that AstraZeneca internal documents reveal intense effort to imitate competitors, placate study investigators.
Seroquel Marketing Plan Included “Spinning The Data, aka Lilly”
Plantiffs attorneys allege that AstraZeneca internal documents reveal intense effort to imitate competitors, placate study investigators.
Lundbeck’s Serdolect and AstraZeneca’s Seroquel XR To Face Advisory Panel Review
FDA’s Psychopharmacologic Drug Advisory Committee will evaluate the applications for the two antipsychotics in a two day meeting in April.